ABSTRACT
A simple, reliable a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, (MTS) assay was conducted to evaluate the potential cytotoxic effects of levodopa, a “gold standard therapy” for Parkinsonism, and its complex with Hydroxypropyl-β-Cyclodextrin (HP-β-CD) on an astrocyte cell line. The cells were incubated in a range of concentrations from 4.69 to 300 μg/mL levodopa, HP-β-CD or the complex for up to 72 hours. At every 24-hour interval, the optical density (OD), which reflects the number of viable cells, was recorded. In general, linear dose-dependent cytotoxicity profiles were observed for the cells subjected to levodopa or the complex, whereas a slightly triphasic response was observed for the cells exposed to HP-β-CD. A significant difference (P 200 μg/mL), exhibited improved tolerability in a time-dependent manner, which may indicate the potential ability of HP-β-CD to mask the toxic effects of levodopa via complexation.
ABSTRACT
The possible cytotoxic effects of vancomycin and its complex with beta-cyclodextrin [beta-CD] on human glial cell line [CRL 8621] were studied accordingly by means of MTS assay. The cultured cells were incubated with various concentrations of vancomycin, beta-CD as well as beta-CD/vancomycin complex ranging from 4.69 to 300 ug/ml. A linear dose-dependency cytotoxicity followed by hermetic-like biphasic dose-dependence was observed after incubation period of 72 hours. In general, significant increase [p<0.001] of cell proliferation was observed at lower concentrations: /= 150 micro g/ml. In particular, 50% inhibitory in vitro was achieved at the concentrations of 115.95 microg/ml [for beta-CD], 116.48 micro g/ml [for vancomycin] and 115.44 microg/ml [for beta-CD/vancomycin complex]